Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prevention and treatment of bronchopulmonary dysplasia: current status and future prospects

Journal of Perinatology volume 27, pages S26–S32 (2007)Cite this article

Abstract

This review summarizes the existing evidence for potential non-ventilator-dependent strategies to prevent or ameliorate bronchopulmonary dysplasia (BPD). Oxygen plays an important pathogenetic and therapeutic role for BPD. Targeting infants with lower saturation of peripheral oxygen levels than traditionally used seems justified. Inhaled nitric oxide has not proven effective on pulmonary outcome in extremely low birth weight infants. Diuretics can ameliorate lung function transiently. High intramuscular doses of vitamin A reduce the risk of BPD. Prophylactic application of natural surfactant may also confer benefits. Recently, early administration of caffeine has been shown to decrease risk of BPD. However, assessment of long-term effects is needed before routine use can be recommended. Owing to potential short- and long-term effects, postnatal corticosteroids should be restricted to the most severe manifestations of BPD. Superoxide dismutase and α1-proteinase inhibitor have not shown efficacy in preventing BPD. The potential role of anti-inflammatory therapies like Clara Cell 10 kDa protein has yet to be defined.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jobe AH, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723–1729.

    Article  CAS  Google Scholar 

  2. Speer CP . Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med 2006; 11: 354–362.

    Article  Google Scholar 

  3. Speer CP . Pulmonary inflammation and bronchopulmonary dysplasia. J Perinatol 2006; 26: S57–S62.

    Article  CAS  Google Scholar 

  4. Van Marter LJ . Progress in discovery and evaluation of treatments to prevent bronchopulmonary dysplasia. Biol Neonate 2006; 89: 303–312.

    Article  Google Scholar 

  5. Thomas W, Speer CP . Management of infants with bronchopulmonary dysplasia in Germany. Early Hum Dev 2005; 81: 155–163.

    Article  Google Scholar 

  6. Saugstad OD . Chronic lung disease: oxygen dogma revisited. Acta Paediatr 2001; 90: 113–115.

    Article  CAS  Google Scholar 

  7. Saugstad OD, Ramji S, Vento M . Resuscitation of depressed newborn infants with ambient air or pure oxygen: a meta-analysis. Biol Neonate 2005; 87: 27–34.

    Article  Google Scholar 

  8. Lundstrom KE, Pryds O, Greisen G . Oxygen at birth and prolonged cerebral vasoconstriction in preterm infants. Arch Dis Child Fetal Neonatal Ed 1995; 73: F81–F86.

    Article  CAS  Google Scholar 

  9. Tin W, Milligan DW, Pennefather P, Hey E . Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 2001; 84: F106–F110.

    Article  CAS  Google Scholar 

  10. The STOP-ROP Multicenter Study Group. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105: 295–310.

    Article  Google Scholar 

  11. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM . Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003; 349: 959–967.

    Article  CAS  Google Scholar 

  12. Coalson JJ . Pathology of chronic lung disease of early infancy. In: Bland RD, Coalson JJ (eds). Chronic Lung Disease in Early Infancy. Marcel Dekker: New York, 2000, pp 85–124.

    Google Scholar 

  13. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336: 597–604.

    Article  Google Scholar 

  14. Hascoet JM, Fresson J, Claris O, Hamon I, Lombet J, Liska A et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146: 318–323.

    Article  CAS  Google Scholar 

  15. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354: 1061–1065.

    Article  CAS  Google Scholar 

  16. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P . Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099–2107.

    Article  CAS  Google Scholar 

  17. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353: 13–22.

    Article  CAS  Google Scholar 

  18. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 2006; 355: 343–353.

    Article  CAS  Google Scholar 

  19. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006; 355: 354–364.

    Article  CAS  Google Scholar 

  20. Barrington KJ, Finer NN . Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2006; 1: doi:10.1002/14651858.CD000509.pub2.

  21. Soll RF, Morley CJ . Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001; 2: doi:10.1002/14651858.CD000510.

  22. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F . Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997; 100: E4.

    Article  CAS  Google Scholar 

  23. Brion LP, Primhak RA . Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; 1: doi:10.1002/14651858.CD001453.

  24. Brion LP, Primhak RA, Ambrosio-Perez I . Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002; 1: doi:10.1002/14651858.CD001817.

  25. Brion LP, Primhak RA, Yong W . Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2006; 3: CD001694.

    Google Scholar 

  26. Henderson-Smart DJ, Steer P . Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001; 3: doi:10.1002/14651858.CD00140.

  27. Schmidt B . Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Biol Neonate 2005; 88: 208–213.

    Article  CAS  Google Scholar 

  28. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354: 2112–2121.

    Article  CAS  Google Scholar 

  29. Shenai JP . Vitamin A supplementation in very low birth weight neonates: rationale and evidence. Pediatrics 1999; 104: 1369–1374.

    Article  CAS  Google Scholar 

  30. Spears K, Cheney C, Zerzan J . Low plasma retinol concentrations increase the risk of developing bronchopulmonary dysplasia and long-term respiratory disability in very-low-birth-weight infants. Am J Clin Nutr 2004; 80: 1589–1594.

    Article  CAS  Google Scholar 

  31. Verma RP, McCulloch KM, Worrell L, Vidyasagar D . Vitamin A deficiency and severe bronchopulmonary dysplasia in very low birthweight infants. Am J Perinatol 1996; 13: 389–393.

    Article  CAS  Google Scholar 

  32. Pearson E, Bose C, Snidow T, Ransom L, Young T, Bose G et al. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992; 121: 420–427.

    Article  CAS  Google Scholar 

  33. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340: 1962–1968.

    Article  CAS  Google Scholar 

  34. Wardle SP, Hughes A, Chen S, Shaw NJ . Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001; 84: F9–F13.

    Article  CAS  Google Scholar 

  35. Darlow BA, Graham PJ . Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2002; 4: doi:10.1002/14651858.CD000501.

  36. Ambalavanan N, Wu TJ, Tyson JE, Kennedy KA, Roane C, Carlo WA . A comparison of three vitamin A dosing regimens in extremely-low-birth-weight infants. J Pediatr 2003; 142: 656–661.

    Article  CAS  Google Scholar 

  37. Ambalavanan N, Kennedy K, Tyson J, Carlo WA . Survey of vitamin A supplementation for extremely-low-birth-weight infants: is clinical practice consistent with the evidence? J Pediatr 2004; 145: 304–307.

    Article  CAS  Google Scholar 

  38. Urlichs F, Speer CP . Neutrophil function in preterm and term infants. NeoReviews 2004; 10: e417–e429.

    Article  Google Scholar 

  39. Saugstad OD . Oxidative stress in the newborn – a 30-year perspective. Biol Neonate 2005; 88: 228–236.

    Article  CAS  Google Scholar 

  40. Gerber CE, Bruchelt G, Stegmann H, Schweinsberg F, Speer CP . Presence of bleomycin-detectable free iron in the alveolar system of preterm infants. Biochem Biophys Res Commun 1999; 257: 218–222.

    Article  CAS  Google Scholar 

  41. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr 2003; 143: 713–719.

    Article  CAS  Google Scholar 

  42. Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O . N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate 2004; 86: 275–279.

    Article  CAS  Google Scholar 

  43. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Friedman A . Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr 1984; 105: 781–785.

    Article  CAS  Google Scholar 

  44. Davis JM, Rosenfeld WN, Richter SE, Parad MR, Gewolb IH, Spitzer AR et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100: 24–30.

    Article  CAS  Google Scholar 

  45. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W . Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469–476.

    Article  Google Scholar 

  46. Speer CP, Ruess D, Harms K, Herting E, Gefeller O . Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993; 91: 794–799.

    CAS  Google Scholar 

  47. Speer CP . New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79: 205–209.

    Article  CAS  Google Scholar 

  48. Dunn MS, Stiskal JA, O'Brien KK, Ito S, Cox DW, Kelly EN . Alpha-1 proteinase inhibitor (A1PI) therapy for the prevention of chronic lung disease of prematurity (CLD) – a dose ranging study an meta analysis with previous randomized clinical trial (RCT). Pediatr Res 2000; 47: 397A.

    Google Scholar 

  49. Stiskal JA, Dunn MS, Shennan AT, O'Brien KK, Kelly EN, Koppel RI et al. Alpha1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics 1998; 101: 89–94.

    Article  CAS  Google Scholar 

  50. Shah P, Ohlsson A . Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2001; 3: doi:10.1002/14651858.CD002775.

  51. Shijubo N, Kawabata I, Sato N, Itoh Y . Clinical aspects of Clara cell 10-kDa protein/uteroglobin (secretoglobin 1A1). Curr Pharm Des 2003; 9: 1139–1149.

    Article  CAS  Google Scholar 

  52. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005; 58: 15–21.

    Article  CAS  Google Scholar 

  53. Halliday HL, Ehrenkranz RA, Doyle LW . Early postnatal (<96 h) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: doi:10.1002/14651858.CD001146.

  54. Halliday HL, Ehrenkranz RA, Doyle LW . Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1: CD001145.

    Google Scholar 

  55. Halliday HL, Ehrenkranz RA, Doyle LW . Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; 1; doi:10.1002/14651858.CD001144.

  56. Shinwell ES . Benefits and risks of dexamethasone and hydrocortisone in the preterm infant. Biol Neonate 2005; 88: 255–256.

    Google Scholar 

  57. Shah SS, Ohlsson A, Halliday H, Shah VS . Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev 2003; 1: doi:10.1002/14651858.CD002057.

  58. Shah V, Ohlsson A, Halliday HL, Dunn MS . Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2000; 1: doi:10.1002/14651858.CD001969.

  59. Watterberg K . Anti-inflammatory therapy in the neonatal intensive care unit: present and future. Semin Fetal Neonat Med 2006; 27: 396–401.

    Google Scholar 

  60. Schelonka RL, Katz B, Waites KB, Benjamin Jr DK . Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 2005; 24: 1033–1039.

    Article  Google Scholar 

  61. Castro-Alcaraz S, Greenberg EM, Bateman DA, Regan JA . Patterns of colonization with Ureaplasma urealyticum during neonatal intensive care unit hospitalizations of very low birth weight infants and the development of chronic lung disease. Pediatrics 2002; 110: e45.

    Article  Google Scholar 

  62. Groneck P, Schmale J, Soditt V, Stutzer H, Götze-Speer B, Speer CP . Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. Pediatr Pulmonol 2001; 31: 331–338.

    Article  CAS  Google Scholar 

  63. Jonsson B, Rylander M, Faxelius G . Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr 1998; 87: 1079–1084.

    Article  CAS  Google Scholar 

  64. Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW . Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78: F10–F14.

    Article  CAS  Google Scholar 

  65. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL . Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev 2003; 4: doi:10.1002/14651858.CD003744.

Download references

Acknowledgements

Parts of this article were presented at Evidence vs Experience in Neonatal Practices, Boston, June 2006.

Author information

Authors and Affiliations

  1. University Children's Hospital, Würzburg, Germany

    W Thomas & C P Speer

Authors
  1. W Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C P Speer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C P Speer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, W., Speer, C. Prevention and treatment of bronchopulmonary dysplasia: current status and future prospects. J Perinatol 27 (Suppl 1), S26–S32 (2007). https://doi.org/10.1038/sj.jp.7211723

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7211723

Keywords

This article is cited by

Search

Advanced search

Quick links